Laser Photobiomodulation Therapy to Treat Neuropathic Pain Caused by Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients
A Randomized, Placebo-Controlled Phase II Clinical Trial
Led by Institut du Cancer de Montpellier - Val d'Aurelle · Updated on 2026-07-28
70
Participants Needed
2
Research Sites
30 weeks
Total Duration
AI-Summary
What this Trial Is About
Chemotherapy-induced peripheral neuropathy CIPN is a common side effect experienced by cancer patients after chemotherapy, causing symptoms such as numbness, pain, and sensory changes typically in the hands and feet. Neuropathic pain is a major feature of CIPN and can significantly reduce quality of life by contributing to psychological distress, risk of falls, cognitive difficulties, and sleep problems. There are currently no proven preventive treatments for CIPN, and drug options for neuropathic pain relief remain limited. This trial aims to evaluate the effectiveness, feasibility, and safety of laser photobiomodulation PBM as a treatment for neuropathic pain in CIPN patients.
Participants will receive photobiomodulation therapy using an ATP38 device that delivers laser light at specific wavelengths to the hands andor feet. The treatment consists of two sessions per week for four weeks, totaling eight sessions. Each session lasts 13 minutes, with laser light applied in a counterbalanced order between feet and hands. Certified clinicians will administer the therapy while patients are seated and wear protective glasses. A control group will receive sham therapy mimicking the procedure without active laser light, with an option to receive real treatment after the study.
During the study, participants will be assessed for neuropathic pain and other related symptoms at baseline, throughout treatment, and up to 12 weeks after treatment completion, with additional follow-up up to 6 months. Evaluations include pain intensity, quality of life, sleep disorders, neurocognitive function, and emotional distress. Researchers will also monitor treatment adherence and safety. The total duration of participation spans from the start of treatment through extended follow-up visits to track pain evolution and potential benefits of photobiomodulation therapy.
CONDITIONS
Brief Title
Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy in Cancer Patients
Research Team
A
Aurore MOUSSION
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Significant neuropathic pain with a clinician-rated DN4 score of 4 or higher
Neuropathic pain lasting at least 3 months after completion of adjuvant or neo-adjuvant chemotherapy
Negative pregnancy test within 7 days before treatment for women of childbearing potential
Effective contraception for women of childbearing age
Signed informed consent before any study procedure
Affiliated with French social protection system
Sufficient fluency in French to complete questionnaires as judged by investigator
You will not qualify if you...
Unable to attend treatment sessions twice a week
Unable to sit for approximately 30 minutes
Open wound or ulcer on treatment areas (hands and/or feet)
Peripheral neuropathy caused by other conditions (except diabetes without neuropathy)
Uncontrolled psychiatric illness or neurocognitive impairment affecting assessments
Estimated life expectancy less than 3 months
Use of other non-pharmacological or complementary therapies for neuropathy during the study
Capsaicin treatment within the last 3 months
Presence of pacemaker
Epilepsy diagnosis
Use of photosensitive medications or conditions causing light sensitivity (e.g., Lupus)
Pregnant or breastfeeding women
Primary tumor or metastases in treatment areas
Pre-existing or family history of eye diseases such as maculopathy, glaucoma, cataract, or retinal lesions
Previous photobiomodulation treatment on target areas
Participation in another clinical study targeting neuropathic pain or chemotherapy-induced peripheral neuropathy
Presence of tattoos on the treatment areas
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 4 weeks
Participants attend photobiomodulation sessions twice a week for four weeks, receiving laser therapy or sham treatment on the hands and/or feet.
2 visits per week (8 sessions total)
Follow-up
Duration - 6 months
Participants are monitored for neuropathic pain, quality of life, sleep disorders, and neurocognitive function for up to 6 months after treatment.
Periodic assessments during follow-up
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Using a Smartphone App to Help Young Adults with Chronic Kidney Disease Follow the 2024 KDIGO Care Guidelines
Phase 2a Study of GI-102 and GIB-7 Combination to Improve Aging Biomarkers in Healthy Adults and Cancer Survivors
Feasibility Study of Social Needs Screening and Referral for Cancer Survivors in Metro Detroit
Study on Sleep Quality in Cancer Survivors Diagnosed Between Ages 15 and 24
High-Intensity CrossFit Training to Improve Movement and Quality of Life in Adult Cancer Survivors
Study of Safety and Effectiveness of Peripheral Nerve Stimulation for Adults with Peripheral Neuropathic Pain
EMDR Therapy to Reduce Chemotherapy-Induced Nausea and Vomiting in Cancer Survivors
Laser Photobiomodulation Therapy to Treat Neuropathic Pain Caused by Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients
A Randomized, Placebo-Controlled Phase II Clinical Trial
Exercise Training and Nicotinamide Riboside Supplement to Improve Muscle Strength and Fitness in Adolescents and Young Adults After Hematopoietic Cell Transplant
Online Psychological Treatment Study for Adult Cancer Survivors with Anxiety or Depression
Assessing Different Therapy Components Over 10 Weeks
The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial).